In this study, we observed that two of the most commonly used AR-antagonists, enzalutamide and bicalutamide, caused significant induction of cell migration in AR-positive prostate cancer cells, indicating that treatment with these drugs may lead to unintended consequences resulting in the development or aggravation of metastatic disease. The gene discussed is AR; the disease is prostate carcinoma.